

IN THE CLAIMS:

Please cancel Claims 15, 16, 19 and 22, without prejudice.

Please amend the claims as follows:

1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)

17. (currently amended) An anti pneumococcal pharmaceutical composition comprising:

(a) at least two therapeutically effective anti pneumococcal lytic enzymes obtained from bacteriophage, wherein said at least two bacteriophage derived lytic enzymes are selected from the group consisting of an amidase and a muramidase; and

(b) a carrier suitable for delivery of the lytic enzymes to the site of infection;

wherein the combination of the at least two enzymes in the composition shows more than

additive pneumococcal killing on a logarithmic scale ~~The pharmaceutical composition of claim 16,~~ and wherein the amidase is Pal and the muramidase is Cpl-1.

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (currently amended) An anti-microbial composition for sanitizing or decontaminating porous or non-porous surfaces suspected of containing *Streptococcus pneumoniae* comprising at least two anti-microbial lytic enzymes obtained from bacteriophage, wherein said at least two bacteriophage derived lytic enzymes are selected from the group consisting of an amidase and a muramidase, wherein the combination of the at least two enzymes in the composition shows more than additive *Streptococcus pneumoniae* killing on a logarithmic scale ~~The composition of claim 22,~~ and wherein the amidase is Pal and the muramidase ~~lysozyme~~ is Cpl-1.

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)